Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.

Fiche publication

Date publication

mars 2025

Journal

RMD open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40037922

Résumé

Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse cardiovascular events (MACE), venous thromboembolism (VTE) and malignancies.